Lymphoma cancer is a type of cancer that begins in the lymphatic system, where abnormal lymphocytes (a kind of white blood cell) grow uncontrollably and form tumors that can spread throughout the body. It is…
FDA Approval Of Rylaze Fills Asparaginase Shortage Gap, Offers New Hope For ALL/LBL Patients In June 2021, the U.S. Food and Drug Administration (FDA) approved Rylaze (JZP458, recombinant Owenella asparaginase) for the treatment of patients…
Folotyn (generic name: Pralatrexate), the first drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), has made a number of important advances worldwide…
March 29, 2025 – Horizon Therapeutics, the manufacturer of Actimmune® (interferon gamma-1b), has announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for the treatment of severe malignant osteopetrosis in pediatric patients. This decision follows…
In a significant advancement in the fight against leukemia, Iclusig (ponatinib) continues to demonstrate its effectiveness as a potent tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic…
Recently, the U.S. Food and Drug Administration (FDA) announced the accelerated approval of Jaypirca (generic name: pirtobrutinib) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received BTK…
Recently, the U.S. Food and Drug Administration (FDA) officially approved Carvykti (Ciltacabtagene Autoleucel, or Cilta-cel), a CAR-T cell therapy jointly developed by Johnson & Johnson and Legend Biotech, for the treatment of adult patients with…
February 2025 — In a significant breakthrough for cancer treatment, Loncastuximab Tesirine-lpyl (brand name Zynlonta) is rapidly gaining attention as a promising new option for patients with relapsed or refractory large B-cell lymphoma (LBCL). Recently…
In the rapidly advancing world of cancer treatment, Lunsumio(Mosunetuzumab) has emerged as a promising new therapy, offering hope to patients with certain types of B-cell non-Hodgkin lymphoma (NHL). This cutting-edge bispecific monoclonal antibody is poised…
In the ever-evolving landscape of medical science, a new development has caught the attention of the healthcare community – Chloroxoquinoline Capsules. These capsules are emerging as a potential game-changer in the treatment of several health…
Etoposide soft capsule have emerged as an important treatment option for a variety of cancers, providing an effective and convenient alternative to traditional chemotherapy regimens. Etoposide, a potent chemotherapeutic agent, has been used for decades…
Compound Cyclophosphamide, a powerful chemotherapy drug, continues to play a central role in the treatment of various cancers and autoimmune diseases. As one of the most effective alkylating agents, this compound is helping thousands of…
